VISTA-101: A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA alone and in combination with pembrolizumab in advanced solid tumors
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023
Frontiers in Oncology : Clinical and Research Updates on the VISTA Immune Checkpoint: Immuno-oncology Themes and Highlights
Randolph J. Noelle, J. Louise Lines, Lionel D. Lewis, Robert E. Martell, Thierry Guillaudeux, Sam W. Lee, Kathleen M. Mahoney, Matthew D. Vesely, Jerome Boyd-Kirkup, Dhanya K. Nambiar and Andrew M. Sc ...
VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2023 | April 16, 2023
Next-generation immunotherapies to address cancer immune resistance
Thierry Guillaudeux, PhD, Chief Scientific Officer Antibody Engineering & Therapeutics Conference | December 7, 2022
KVA12123: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity
Thierry Guillaudeux, PhD, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2022 | November, 2022
KVA 12.1 a novel fully human anti-VISTA antibody to treat cancer patients with advanced solid tumors
Shaarwari Sridhar, Scientist at Kineta Tumor Myeloid-Directed Therapies Summit 2022 | June 14, 2022
KVA 12.1 a novel fully human anti-VISTA antibody clinical trial design in monotherapy and in combination with an anti-PD1 antibody
Thierry Guillaudeux, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2021 | November, 2021
A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2021 | April, 2021
Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of VISTA to Its Putative Receptors at Different pH
Thierry Guillaudeux, PhD, Chief Scientific Officer European Society for Medical Oncology (ESMO) Virtual Congress 2020 | December 9, 2020